See more : Itaú Corpbanca (ITCB) Income Statement Analysis – Financial Results
Complete financial analysis of Stealth BioTherapeutics Corp (MITO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stealth BioTherapeutics Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Priority Income Fund, Inc. (PRIF-PD) Income Statement Analysis – Financial Results
- Azrieli Group Ltd (AZRGF) Income Statement Analysis – Financial Results
- Evaxion Biotech A/S (EVAX) Income Statement Analysis – Financial Results
- People & Technology Inc. (137400.KQ) Income Statement Analysis – Financial Results
- Acheter-Louer.Fr SA (ALALO.PA) Income Statement Analysis – Financial Results
Stealth BioTherapeutics Corp (MITO)
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.56M | 29.31M | 44.60M | 53.06M | 63.22M | 48.45M |
| General & Administrative | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Cost & Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Interest Income | 3.00K | 139.00K | 988.00K | 195.09K | 56.84K | 799.02K |
| Interest Expense | 1.24M | 1.81M | 6.67M | 21.36M | 3.28M | 0.00 |
| Depreciation & Amortization | 77.00K | 232.00K | 284.00K | 309.04K | 346.87K | 312.54K |
| EBITDA | -51.21M | -55.42M | -64.78M | -75.05M | -79.28M | -60.74M |
| EBITDA Ratio | 0.00% | 0.00% | -307.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -51.29M | -48.67M | -45.83M | -75.28M | -79.72M | -61.85M |
| Operating Income Ratio | 0.00% | 0.00% | -217.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.22M | -8.79M | -25.90M | -21.43M | -3.19M | 799.02K |
| Income Before Tax | -52.53M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | -6.98M | -19.23M | -76.21K | 92.30K | 799.02K |
| Net Income | -53.77M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Net Income Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| EPS | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| EPS Diluted | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| Weighted Avg Shares Out | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
| Weighted Avg Shares Out (Dil) | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
Analysts Anticipate Stealth BioTherapeutics Corp (NASDAQ:MITO) Will Post Earnings of -$0.04 Per Share
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
Overcoming the Challenges of CRM at Your Small Business
The Power of Instagram Influencers for Your Small Business
Source: https://incomestatements.info
Category: Stock Reports